GlassScriptPhysician profile
Donald G Cunningham
NPI 1508855719
$8,604.73
in general payments reported to CMS, 2019-2025
41 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $896 · 2021: $1,686 · 2022: $1,460 · 2023: $1,396 · 2024: $1,148 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862 · Entertainment: $21.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.94 |
| Entertainment | $21.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,393.55 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,349.30 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Janssen Biotech, INC. | $1,026.16 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $711.80 | 2020-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $555.91 | 2021-2024 | Mavyret, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $425.06 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $274.62 | 2019-2025 | Freestyle Libre 2, Gallant, Octrode |
| Novo Nordisk INC | $198.60 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $159.06 | 2020-2023 | |
| Emd Serono, INC. | $137.80 | 2025 | |
| Amgen INC. | $130.69 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Lucid Diagnostics INC. | $130.04 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.29 | 2019-2024 | Jardiance |
| Medtronic, INC. | $103.23 | 2021-2024 | Intellis Adaptivestim, Micra |
| Glaxosmithkline, LLC. | $96.11 | 2019-2023 | Trelegy Ellipta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $90.87 | 2019-2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $82.15 | 2022-2024 | Spravato |
| Theratechnologies INC. | $72.14 | 2020-2022 | |
| Eisai INC. | $67.15 | 2020-2024 | |
| Hologic Sales and Service, LLC | $40.59 | 2023 | Aptima |
| Sanofi Pasteur INC. | $40.54 | 2019 | |
| Amarin Pharma, INC. | $33.96 | 2019-2021 | |
| Exact Sciences Corporation | $31.17 | 2023-2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $24.92 | 2020 | |
| Nestle Healthcare Nutrition INC. | $24.13 | 2022 | |
| Mylan Specialty L.P. | $22.64 | 2021 | |
| Optos, INC. | $21.48 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alnylam Pharmaceuticals INC. | $20.86 | 2023 | Givlaari |
| Scilex Pharmaceuticals INC. | $19.53 | 2022 | |
| Napo Pharmaceuticals INC | $18.13 | 2025 | Mytesi |
| Biogen, INC. | $18.10 | 2021 | |
| Boston Scientific Corporation | $17.66 | 2021 | |
| Horizon Therapeutics Plc | $17.33 | 2023 | Krystexxa |
| Intra-Sana Laboratories | $17.18 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Corcept Therapeutics | $17.05 | 2021 | |
| Allergan, INC. | $16.86 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.04 | 2021 | |
| Teleflex LLC | $15.19 | 2024 | Urolift |
| Sanofi-Aventis U.S. LLC | $14.92 | 2024 | |
| Lilly USA, LLC | $14.00 | 2022 | |
| Clarus Therapeutics INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.